Az alábbi szakirodalmi jegyzékban található cikkek, tanulmányok, publikációk az adott sorra kattintva PDF dokumentum formájában megnyithatók és elolvashatók.

1. Szekanecz Z, Nagy G (2024): A mátrix metalloproteináz 3 (MMP-3) jelentősége rheumatoid arthritisben. Immunológiai Szemle, 2024. XVI. évfolyam, 4. szám pp. 15-19.
2. Meznerics F. A., Kemény L. V., Gunther E., Bakó E., Dembrovszky F., Szabó B., Ascsillán A., Lutz E., Csupor D., Hegyi P., Bánvölgyi A., Nagy G. (2023): Multibiomarker disease activity score: an objective tool for monitoring rheumatoid arthritis? A systematic review and meta-analysis . Rheumatology. Vol. 62 No. 6, pp. 2048-2059.
3. Skacelova M., Hermanova Z., Horak P., Ahmed K., Langova K. (2017): Higher level of matrix metalloproteinase-3 in patients with RA reflect disease activity and structural damage. Biomed Pap Meg Fax Univ Palacky Olomouc Czech Republikánus. Vol. 161. No. 3., pp. 296-302.
4. Bian Y., Xiang Z., Wang Y., Rendszere Q., Chen G., Xiang B., Wang J., Zhang C., Pei S., Guo S., Xiao L. (2023): Immunomodulatory roles of metalloproteinases in rheumatoid arthritis. Front Pharmacol. Vol. 14, e1285455.
5. Wan J., Zhang G., Li X., Qiu X., Ouyang J., Mai J., Min S. (2021): Matrix Metalloproteinase 3: A Promoting and Destabilizing Factor in the Pathogenesis of Disease and Cell Differentiation. Front Physiol. Vol. 12, e663978.
6. Lerner A., Neidhöfer S., Reuter S., Matthias T. (2018): MMP3 is a reliable marker for disease activity, radiological monitoring, disease outcome predictability, and therapeutic response in rheumatoid arthritis. Best Pract Res Clin Rheumatol. Vol. 32 No. 4., pp. 550-562.
7. Hameed M. R., Khaleel F. M., Gorial F. I. (2024): Glaectin-3, Matrix Metalloproteinase-3 and TLR-2 Receptor as Novel Biomarkers in the Diagnosis of Rheumatoid Arthritis. Al-Raifdan Journal of Medical Sciences. ISSN 2789-3219.
8. Liang Z., Wang N., Shang L., Wang Y., Feng M., Liu G., Gaz C., Luo J. (2022): Evaluation of the immun feature of ACPA-negative rheumatoid arthritis and the clinical value of Matrix metalloproteinase-3. Front Immunol. Vol. 27. No. 13., e939265.
9. Posthumus M. D., Limburg P. C., Westra J., van Leeuwen M. A., van Rijswijk M. H. (2000): Serum matrrix metalloproteinase 3 in early rheumatoid arthritis is correlated with disease actiity and radiological progression. J Rheumatol. Vol. 27. No. 12., pp.2761-268.
10. Houseman M., Potter C., Marshall N., Lakey R., Cawston T., Griffiths I., Young-Min S., Isaacs J. D. (2012): Baseline serum MMP-3 levels in patients with Rheumatoid Arthritis are Still independently predictive of radiographic progression in a longitudinal obserevational cohort at 8 years follow up. Arthritis Res Ther. Vol. 14. No. R30.
11. Hattori Y., Kida D., Kaneko A. (2019): Normal serum matrix metalloproteinase-3 levels can be used to predict clinical remission and normal physical function in patients with rheumatoid arthritis. Clinton Rheumatol. Vol. 38. pp. 181-187.
12. Galil S. M., El-Shafey A. M., Hagrass H.A., Fawzy F., Sammak A. E. (2016): Baseline serum level of matrix metalloproteinase-3 as biomarker of progressive joint damage in rheumatoid arthritis patients. Int J Rheum Dis. Vol. 19. No. 4., pp. 377-384.
13. Takemoto T., Takahashi N., Kida D., Kaneko A., Hirano Y., Fujibayashi T., Kanayama Y., Hanabayashi M., Yabe Y., Takagi H., Oguchi T., Kato T., Funahashi K., Matsumoto T., Sobue Y., Nishiume T., Suzuki M., Yokota Y., Terabe K., Asai S., Ishiguro N., Kojima T. (2020): Improvement in matrix metalloproteinase-3 independently predicts low disease activity at 52 weeks in bio-switch rheumatoid arthritis patients treated with abatacept. Clin Exp Rheumatol. Vol. 38 No.5., pp. 933-939.
14. Smolen J.S., Landewé R. B. M., Bijlsma J. W. J., Burmester G. R., Dougados M., Kerschbaumer A., McInnes I. B., Sepriano A., van Vollenhoven R. F., de Wit M., Aletaha D., Aringer M., Askling J., Balsa A., Boers M., den Broeder A. A., Buch M. H., Buttgereit F., Caporali R., Cardiel M. H., De Cock D., Codreanu C., Cutolo M., Edwards C. J., van Eijk-Hustings Y., Emery P., Finckh A., Gossec L., Gottenberg J. E., Hetland M. L., Huizinga T. W. J., Koloumas M., Li Z., Mariette X., Müller-Ladner U., Mysler E. F., da Silva J. A. P., Poór G., Pope J. E., Rubbert-Roth A., Ruyssen-Witrand A., Saag K. G., Strangfeld A., Takeuchi T., Voshaar M., Westhovens R., van der Heijde D. (2019): EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. Vol. 79. No. 6., pp. 685-699.
15. Alamanos Y., Voulgari P. V., Drosos A. A. (2006): Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of Rheumatology criteria: a systematic review. Semin Arthritis Rheum. Vol. 36. No. 3., pp. 182-188.
16. Nagy G., Roodenrijs N. M. T., Welsing P. M. J., Kedves M., Hamar A., van der Goes M. C., Kent A., Bakkers M., Pchelnikova P., Blaas E., Senolt L., Szekanecz Z., Choy E. H., Dougados M., Jacobs J. W., Geenen R., Bijlsma J. W., Zink A., Aletaha D., Schoneveld L., van Riel P., Dumas S., Prior Y., Nikiphorou E., Ferraccioli G., Schett G., Hyrich K. L., Mueller-Ladner U., Buch M. H., McInnes I. B., van der Heijde D., van Laar J. M. (2022): EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis. Ann Rheum Dis. Vol. 81 No.1., pp. 20-33.
17. Hideto Kameda, Kunihiro Yamaoka, Yuji Yamanishi, Masahiro Tada, Ryuji Koike, Ayako Nakajima, Mie Fusama and Takao Fujii (2023): Japan College of Rheumatology guidance for the use of methotrexate in patients with rheumatoid arthritis: Secondary publication. Modern Rheumatology, 34, 2024, 1–10
18. Slavica Z. Prodanovic, G. Radunovic, Dragan Babic, Biljana Ristic, Mirjana Sefik-Bukilica, Maja Zlatanovic, Katarina Simic-Pasalic, Srdjan Seric Nada Vujasinovic-Stupar, Janko Samardzic, Nemanja Damjanov (2024): Matrix Metalloproteinases-3 Baseline Serum Levels in Early Rheumatoid Arthritis Patients without Initial Radiographic Changes: A Two-Year Ultrasonographic Study. Med Princ Pract 2018;27:378–386
19. Grillet B, Pereira RVS, Van Damme J, Abu El-Asrar A, Proost P, Opdenakker G: Matrix metalloproteinases in arthritis: towards precision medicine. Nat Rev Rheumatol. 2023; 19: 363-377.
20. Ribbens C, Porras MM, Franchimont N, et al: Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment. Ann RheumDis 2002;61:161–166.
21. Kobayashi A, Naito S, Enomoto H, et al: Serum levels of matrix metalloproteinase 3 (stromelysin 1) for monitoring synovitis in rheumatoid arthritis. Arch Pathol Lab Med 2007;131:563–570
22. Pulik L, Legosz P, Motyl G: Matrix metalloproteinases in rheumatoid arthritis and osteoarthritis: a state of the art review. Reumatologia. 2023; 61: 191-201
23. Boeters DM, Burgers LE, Sasso EH, Huizinga TWJ, van der Helmvan Mil AHM: ACPA-negative RA consists of subgroups: patients with high likelihood of achieving sustained DMARD-free remission can be identified by serological markers at disease presentation. Arthritis Res Ther. 2019; 21: 121.
24. Ma JD, Zhou JJ, Zheng DH, Chen LF, Mo YQ, Wei XN, Yang LJ, Dai L. Serum matrix metalloproteinase-3 as a noninvasive biomarker of histological synovitis for diagnosis of rheumatoid arthritis. Mediators Inflamm. 2014;2014:179284. doi: 10.1155/2014/179284. Epub 2014 Jul 23. PMID: 25147433; PMCID: PMC4132319.
25. Ma JD, Wei XN, Zheng DH, Mo YQ, Chen LF, Zhang X, et al: Continuously elevated serum matrix metalloproteinase-3 for 3 ~ 6 months predict one-year radiographic progression in rheumatoid arthritis: a prospective cohort study. Arthritis Res Ther. 2015; 17: 289
26. Samia Fadda, Enas Abolkheir, Rabab Afifi, Mohamad Gamal: Serum matrix metalloproteinase-3 in rheumatoid arthritis patients: Correlation with disease activity and joint destruction. The Egyptian Rheumatologist, Volume 38, Issue 3, 2016, pp 153-159.
27. Tchetverikov I, Lard LR, DeGroot J, Verzijl N, TeKoppele JM, Breedveld FC, Huizinga TW, Hanemaaijer R. Matrix metalloproteinases-3, -8, -9 as markers of disease activity and joint damage progression in early rheumatoid arthritis. Ann Rheum Dis. 2003 Nov;62(11):1094-9.
28. Takeuchi T, Tanaka Y, Morita Y, Kato D, Kaneko Y, Terada W: Association between matrix metalloprotease-3 levels and radiographic progression in patients with rheumatoid arthritis: A post hoc analysis from a Japanese Phase 3 clinical trial of peficitinib (RAJ4). Mod Rheumatol. 2024; 34: 947-953
29. Rajalingham S, Kjn O, Ismail E, Shaharir S, Radikha S: Serum Matrix Metalloproteinase-3 Predicts Radiographic Joint Damage and Functional Disability in Rheumatoid Arthritis. Journal of Medicine & Health. 2016;101; pp209-217.

Jellemzők:

• Vérvétel szükséges
• Nem éhomi vizsgálat, előkészületet a páciens részéről nem igényel
• Eredmény 20 munkanapon belül

Diagnózishoz vagy a terápiás hatás ellenőrzéséhez az eredményeket mindig együtt kell értelmezni a páciens anamnézisével, klinikai vizsgálataival és egyéb leleteivel!

Az MMP-3 szint mérése magánfinanszírozás keretében országosan elérhető az alábbi SYNLAB vérvételi hálózatában és mindazoknál a magánegészségügyi szolgáltatóknál, akik a SYNLAB-bal szerződéses kapcsolatban állnak.